Exploration of IDO1 as a Therapeutic Target in Pediatric Central Nervous System Tumors

Email Principal Investigator
Completed
Specimen
Medulloblastoma
HGG
LGG
Ependymoma
DIPG
Asset 18.png
rishi_lulla.original.jpg

Rishi Ramesh Lulla

The Warren Alpert Medical School of Brown University
Providence, RI

CBTN Specimen

45

CBTN Participants

45

CBTN Samples

Backer

NIH

Neuro-Oncology Research Fund at Lurie Children's Hospital.

Completed

About this

Project

The immune system can suppress and even eradicate tumor growth, but some central nervous system (CNS) tumors have been linked to immune-evasive strategies due to their continued progression. The capability of the immune system to recognize and inhibit the growth of cancer is dependent on its ability to recognize the variety of genetic and epigenetic (non-gene) variations that characterize tumors. A consistent feature of adult glioblastoma is the presence of immunosuppressive regulatory T cells (Treg). These T cells impair a patient’s anti-glioblastoma immune response and the expression of the enzyme indoleamine 2,3 dioxygenase 1 (IDO1). Further data suggests that IDO1 is a high value target for immunotherapeutic consideration in adult glioma. However, whether these findings translate to pediatric brain tumors has yet to be explored. This project aims to determine the level of IDO1 expression in pediatric central nervous system tumors, specifically focusing on low grade glioma, high grade glioma, medulloblastoma and ependymoma. The Children's Brain Tumor Network contributed 16 high-grade glioma samples, 20 low-grade glioma samples, 20 medulloblastoma samples, 18 ependymoma samples and 12 DIPG samples to this project.

Ask The

Scientists

Ask the scientists

What are the goals of this project?

Researchers will interrogate data on pediatric brain tumors in an effort to determine whether enzyme IDO1 could serve as a target for immunotherapy.

What is the impact of this project?

Previous research has pointed to IDO1 as a promising target for the treatment of adult brain tumors and this work will help determine whether IDO1 can also be targeted for the treatment of pediatric brain cancers.

Why is the CBTN request important to this project?

High quality specimens across pediatric brain tumor types are needed to complete this work and were provided to researchers by the Children’s Brain Tumor Network.

Specimen Data

The Children's Brain Tumor Network contributed 16 high-grade glioma samples, 20 low-grade glioma samples, 20 medulloblastoma samples, 18 ependymoma samples and 12 DIPG samples to this project.

related

Histologies